Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 21.
doi: 10.1007/s13300-025-01772-1. Online ahead of print.

Real-World Effectiveness of My Dose Coach™-Assisted Basal Insulin Titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait

Mohammed E Al-Sofiani  1   2 , Mohamed Almehthel  3   4 , Ebaa Al Ozairi  5 , Jamaa Sadik  6 , Lichen Hao  7 , Yasser Akil  8
Affiliations

Real-World Effectiveness of My Dose Coach™-Assisted Basal Insulin Titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait

Mohammed E Al-Sofiani et al. Diabetes Ther. .

Abstract

Introduction: My Dose Coach (MDC) is a digital smartphone application approved in multiple countries, including Saudi Arabia and Kuwait, to help people with type 2 diabetes (T2D) titrate their basal insulin as per their clinician-guided, individualized diabetes care plan.

Methods: A retrospective, observational cohort analysis was conducted on MDC user data collected from 1 January 2021 to 1 June 2023 in Saudi Arabia and Kuwait. Primary outcome was change in fasting blood glucose (FBG). Key secondary outcomes included time to achieve FBG and HbA1c targets, and time to first hypoglycemia event. Outcomes were analyzed by FBG target status and frequency of MDC usage (high: > 3 days per week; moderate: > 1- ≤ 3 days per week; low: ≤ 1 day per week).

Results: Among all users (N = 494), mean ± SD FBG decrease was -44.4 ± 72.5 mg/dL. Mean ± SD time to achieve FBG target was 14.8 ± 20.9 days and 12.8 ± 18.8, 29.1 ± 28.0, and 43.5 ± 41.7 days for high-, moderate-, and low-frequency MDC users, respectively. Individualized FBG targets were achieved by 276 (55.9%) users, and high-frequency of MDC use was associated with better target achievement (p < 0.01). Mean ± SD time to achieve HbA1c target was 48.0 ± 40.5 days. Reduction in HbA1c was more in high-frequency MDC users (18.3%) than low-frequency MDC users (6.3%). Mean ± SD time to the first hypoglycemia event was 4.86 ± 4.8 days. Hypoglycemia events were reported in only seven (1.4%) participants and not significantly correlated with MDC use frequency (p = 0.1431).

Conclusions: Current findings show that using MDC is associated with improved glycemic control in people with T2D in Saudi Arabia and Kuwait, with greater benefits observed with higher frequency MDC usage.

Keywords: Fasting blood glucose; Hypoglycemia; Mobile applications; My Dose Coach; Self-monitoring blood glucose; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: Mohammed E. Al-Sofiani has served on an advisory panel for Abbott, Medtronic, Insulet, VitalAire, and Sanofi and has received honoraria for speaking and consultancy from Abbott, Eli Lilly, Medtronic, Novo Nordisk, Sanofi, and VitalAire; Mohamed Almehthel and Ebaa Al Ozairi have no conflicts of interest to declare; Jamaa Sadik, Lichen Hao, and Yasser Akil are employees of Sanofi and may hold Sanofi shares and/or stock. Ethical Approval: MDC users agreed to allow their anonymized data to be used retrospectively as part of the registration process. The study was approved by the Institutional Review Board of King Saud University (ref. no. 22/0251 /IRB), Saudi Arabia and Kuwait.

Similar articles

See all similar articles

References

    1. IDF Diabetes Atlas 11th Edition. Brussels, Belgium: International Diabetes Federation; 2025. IDF Diabetes Atlas | Global Diabetes Data & Statistics. Accessed 9 April 2025.
    1. Moradinazar M, Babakhani M, Rostami R, Shakiba M, Moradi A, Shakiba E. Epidemiological status of type 2 diabetes mellitus in the Middle East and North Africa, 1990–2019. East Mediterr Health J. 2022;28(7):478–88. - PubMed
    1. El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: challenges and call for action. World J Diabetes. 2021;12(9):1401–25. - PubMed - PMC
    1. Alhagawy AJ, Yafei S, Hummadi A, et al. Barriers and attitudes of primary healthcare physicians to insulin initiation and intensification in Saudi Arabia. Int J Environ Res Public Health. 2022;19(24):16794. - PubMed - PMC
    1. Alsuliman MA, Alotaibi SA, Zhang Q, Durgampudi PK. A systematic review of factors associated with uncontrolled diabetes and meta-analysis of its prevalence in Saudi Arabia since 2006. Diabetes Metab Res Rev. 2021;37(3): e3395. - PubMed

LinkOut - more resources